Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVX 701

Drug Profile

AVX 701

Alternative Names: AVX701; Cancer vaccine VRP-CEA - AlphaVax; Carcinoembryonic antigen [CEA(6D)]-expressing virus-like replicon particle (VRP) immunotherapy - AlphaVax; CEA(6D) VRP vaccine - AlphaVax; VRP-CEA vaccine - AlphaVax; VRP-CEA(6D)

Latest Information Update: 22 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; Duke University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 22 Sep 2015 Phase-I development for Colorectal cancer (Late-stage disease, Second-line therapy or greater) is ongoing in USA (NCT01890213)
  • 30 Nov 2013 Duke University initiates enrolment in a phase I trial for Colorectal cancer (late-stage disease) in the USA (NCT01890213)
  • 16 Jul 2013 Duke University plans a phase I trial for Colorectal cancer (late-stage disease) in USA (NCT01890213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top